379 related articles for article (PubMed ID: 20197548)
21. Distinguishing essential thrombocythemia
Silver RT; Krichevsky S
Haematologica; 2019 Nov; 104(11):2200-2205. PubMed ID: 30948488
[TBL] [Abstract][Full Text] [Related]
22. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.
Mullally A; Poveromo L; Schneider RK; Al-Shahrour F; Lane SW; Ebert BL
Blood; 2012 Jul; 120(1):166-72. PubMed ID: 22627765
[TBL] [Abstract][Full Text] [Related]
23. JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.
Maddali M; Kulkarni UP; Ravindra N; Jajodia E; Arunachalam AK; Suresh H; Venkatraman A; George B; Mathews V; Balasubramanian P
Ann Hematol; 2020 May; 99(5):983-989. PubMed ID: 32277273
[TBL] [Abstract][Full Text] [Related]
24. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
25. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
26. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
[TBL] [Abstract][Full Text] [Related]
27. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
Vannucchi AM; Antonioli E; Guglielmelli P; Rambaldi A; Barosi G; Marchioli R; Marfisi RM; Finazzi G; Guerini V; Fabris F; Randi ML; De Stefano V; Caberlon S; Tafuri A; Ruggeri M; Specchia G; Liso V; Rossi E; Pogliani E; Gugliotta L; Bosi A; Barbui T
Blood; 2007 Aug; 110(3):840-6. PubMed ID: 17379742
[TBL] [Abstract][Full Text] [Related]
28. Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice.
Akada H; Akada S; Hutchison RE; Mohi G
Leukemia; 2014 Aug; 28(8):1627-35. PubMed ID: 24480985
[TBL] [Abstract][Full Text] [Related]
29. Polycythemia vera: the current status of preclinical models and therapeutic targets.
Bartalucci N; Guglielmelli P; Vannucchi AM
Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
[TBL] [Abstract][Full Text] [Related]
30. Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice.
Akada H; Akada S; Hutchison RE; Mohi G
Haematologica; 2012 Sep; 97(9):1389-93. PubMed ID: 22371173
[TBL] [Abstract][Full Text] [Related]
31. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.
Mitsumori T; Nozaki Y; Kawashima I; Yamamoto T; Shobu Y; Nakajima K; Morishita S; Komatsu N; Kirito K
Exp Hematol; 2014 Sep; 42(9):783-92.e1. PubMed ID: 24860972
[TBL] [Abstract][Full Text] [Related]
33. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
Wernig G; Gonneville JR; Crowley BJ; Rodrigues MS; Reddy MM; Hudon HE; Walz C; Reiter A; Podar K; Royer Y; Constantinescu SN; Tomasson MH; Griffin JD; Gilliland DG; Sattler M
Blood; 2008 Apr; 111(7):3751-9. PubMed ID: 18216297
[TBL] [Abstract][Full Text] [Related]
34. Polycythemia vera is not initiated by JAK2V617F mutation.
Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
[TBL] [Abstract][Full Text] [Related]
35. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.
Godfrey AL; Chen E; Pagano F; Ortmann CA; Silber Y; Bellosillo B; Guglielmelli P; Harrison CN; Reilly JT; Stegelmann F; Bijou F; Lippert E; McMullin MF; Boiron JM; Döhner K; Vannucchi AM; Besses C; Campbell PJ; Green AR
Blood; 2012 Sep; 120(13):2704-7. PubMed ID: 22898600
[TBL] [Abstract][Full Text] [Related]
36. A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.
Chapeau EA; Mandon E; Gill J; Romanet V; Ebel N; Powajbo V; Andraos-Rey R; Qian Z; Kininis M; Zumstein-Mecker S; Ito M; Hynes NE; Tiedt R; Hofmann F; Eshkind L; Bockamp E; Kinzel B; Mueller M; Murakami M; Baffert F; Radimerski T
PLoS One; 2019; 14(10):e0221635. PubMed ID: 31600213
[TBL] [Abstract][Full Text] [Related]
37. Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.
Mansier O; Kilani B; Guitart AV; Guy A; Gourdou-Latyszenok V; Marty C; Parrens M; Plo I; Vainchenker W; James C
Blood; 2019 Dec; 134(26):2383-2387. PubMed ID: 31697834
[TBL] [Abstract][Full Text] [Related]
38. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
[TBL] [Abstract][Full Text] [Related]
39. JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.
Li J; Kent DG; Godfrey AL; Manning H; Nangalia J; Aziz A; Chen E; Saeb-Parsy K; Fink J; Sneade R; Hamilton TL; Pask DC; Silber Y; Zhao X; Ghevaert C; Liu P; Green AR
Blood; 2014 May; 123(20):3139-51. PubMed ID: 24692758
[TBL] [Abstract][Full Text] [Related]
40. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.
Xing S; Wanting TH; Zhao W; Ma J; Wang S; Xu X; Li Q; Fu X; Xu M; Zhao ZJ
Blood; 2008 May; 111(10):5109-17. PubMed ID: 18334677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]